• Develop and launch products with highly differentiated value proposition
  
  
• Transform drug development challenges into opportunities
  
  
• Target de-risked or validated opportunities:
  
  
  • Approved molecules that can be reformulated or repositioned to fulfill critical medical needs
    
    
  • Stalled late stage development programs
    
    
  • NDAs that are facing regulatory challenges
    
    
• Speed to market
  
  
• Focus on specialty care market size